Literature DB >> 15487453

Immunohistochemical staining for calretinin is useful for differentiating schwannomas from neurofibromas.

Samson W Fine1, Steve A McClain, Maomi Li.   

Abstract

We studied 25 cases of schwannoma and 42 cases of neurofibroma immunohistochemically with antibodies to calretinin and S-100 protein to explore the potential usefulness of calretinin in differentiating schwannomas from neurofibromas. Of 25 schwannomas, 24 (96%) showed moderate to strong staining for calretinin, with the extent of staining ranging from focal to diffuse. In contrast, only 3 (7%) of 42 neurofibromas displayed focal weak to moderate staining with calretinin. All 42 cases of neurofibromas and all 25 cases of schwannomas showed diffuse moderate to strong staining with S-100 protein. Calretinin also labeled mast cells, whose presence was confirmed further by staining for c-kit, which commonly was present in both tumor types in a scattered individual cell pattern easily differentiated from the clustered pattern of neoplastic spindle cells. Taken together, these results indicate that calretinin is detected in almost all schwannomas and in only a small percentage of neurofibromas, suggesting it is a useful marker for differentiating schwannomas from neurofibromas. Although mast cells present in these 2 neoplasms also react with calretinin, the pattern of staining can be distinguished easily from that of neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15487453     DOI: 10.1309/AGBG-TBRJ-4W0B-C7LN

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  23 in total

Review 1.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

2.  Immunoreactivity for calretinin and keratins in desmoid fibromatosis and other myofibroblastic tumors: a diagnostic pitfall.

Authors:  Stephanie Barak; Zengfeng Wang; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

3.  Symptomatic pericardial schwannoma treated with video-assisted thoracic surgery: a case report.

Authors:  Po-Jen Yun; Tsai-Wang Huang; Yao-Feng Li; Hung Chang; Shih-Chun Lee; Yen-Liang Kuo
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

4.  Glu-tubulin is a marker for Schwann cells and can distinguish between schwannomas and neurofibromas.

Authors:  Josune García-Sanmartín; Susana Rubio-Mediavilla; José J Sola-Gallego; Alfredo Martínez
Journal:  Histochem Cell Biol       Date:  2016-06-09       Impact factor: 4.304

5.  Juxta-adrenal malignant schwannoma with lymph node metastases.

Authors:  Yu Seob Shin; Hyung Jin Kim; Myung Ki Kim
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

6.  A 60-year-old woman with an asymptomatic left lacrimal gland mass found incidentally.

Authors:  Sudip D Thakar; Oded Sagiv; Michael T Tetzlaff; Adel El-Naggar; J Matthew Debnam; Thomas J Kandl; Bita Esmaeli
Journal:  Digit J Ophthalmol       Date:  2017-10-18

7.  Only septal deviation? A tiny schwannoma in the nasal septum.

Authors:  Peng Zhou; Fan Zeng; Jinnan Li; Shixi Liu
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-11-03

Review 8.  Olfactory ensheathing cell tumor with neurofibroma-like features: a case report and review of the literature.

Authors:  Shih-Chieh Lin; Min-Hsiung Chen; Chun-Fu Lin; Donald Ming-Tak Ho
Journal:  J Neurooncol       Date:  2009-08-19       Impact factor: 4.130

9.  Adrenal Schwannoma: A Rare Incidentaloma.

Authors:  Sumit Kumar; Vilvapathy S Karthikeyan; Chikkamoga S Manohar; K Sreelakshmi; Maregowda Shivalingaiah
Journal:  J Clin Diagn Res       Date:  2016-08-01

Review 10.  Certainty of S100 from Physiology to Pathology.

Authors:  Puneeth Horatti Kuberappa; Bhavana Shivanand Bagalad; Anuradha Ananthaneni; Md Asif Kiresur; Guduru Vijay Srinivas
Journal:  J Clin Diagn Res       Date:  2016-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.